Glassman Wealth Services Intellia Therapeutics, Inc. Transaction History

Glassman Wealth Services

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$23.16 - $32.34 $324 - $452	-14 Reduced 9.21%	138 $4,000
Q3 2023 Nov 13, 2023	BUY	$31.62 - $45.78 $1,454 - $2,105	46 Added 43.4%	152 $4,000
Q2 2023 Aug 08, 2023	SELL	$34.58 - $46.03 $311 - $414	-9 Reduced 7.83%	106 $4,000
Q1 2023 May 04, 2023	SELL	$33.3 - $44.82 $2,031 - $2,734	-61 Reduced 34.66%	115 $4,000
Q4 2022 Feb 06, 2023	SELL	$33.21 - $62.69 $1,693 - $3,197	-51 Reduced 22.47%	176 $6,000
Q3 2022 Nov 09, 2022	SELL	$53.92 - $71.7 $700 - $932	-13 Reduced 5.42%	227 $13,000
Q2 2022 Aug 04, 2022	SELL	$38.49 - $76.21 $423 - $838	-11 Reduced 4.38%	240 $12,000
Q1 2022 Aug 23, 2022	BUY	$58.27 - $118.99 $4,078 - $8,329	70 Added 38.67%	251 $18,000
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $7,960 - $10,930	-79 Reduced 30.38%	181 $21,000
Q3 2021 Nov 10, 2021	BUY	$132.37 - $176.78 $11,119 - $14,849	84 Added 47.73%	260 $35,000
Q2 2021 Aug 04, 2021	BUY	$60.88 - $161.91 $243 - $647	4 Added 2.33%	176 $28,000
Q1 2021 May 05, 2021	BUY	$46.59 - $83.68 $93 - $167	2 Added 1.18%	172 $14,000
Q4 2020 Feb 04, 2021	BUY	$18.83 - $63.53 $3,201 - $10,800	170 New	170 $9,000

333

95.3M

1.06M

863K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $550M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

Stay updated on Glassman Wealth Services with notifications on news.